Institutional investors purchased a net $43.8 million shares of VRX during the quarter ended June 2016 and now own 66.52% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Pharmaceuticals: Other industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
HEXAVEST, INC. Bought 2.0 Million shares of Valeant Pharmaceuticals